1. Home
  2. Services

Clear answers for both sides of a rare neurology deal

We do not import, distribute or sell medicines. That is why both sides can trust our view. Every engagement starts with a written proposal that fixes the question, timeline and fee.

Assessment

Türkiye opportunity assessment

Is Türkiye worth it for your therapy, by which route, and when? A decision-ready answer for your leadership team and board.

Duration
3–5 weeks
Fee
Fixed, agreed in the proposal
Output
Report in English and a one-hour presentation
Discuss an assessment

You receive

  • Estimated patient numbers and diagnosis rate
  • Diagnosing and treating centres
  • Regulatory and reimbursement status with TİTCK and SGK
  • Recommended route: named-patient supply, local licence or both, with timelines
  • Pricing outlook under Türkiye's reference-pricing rules
  • Five-year patient and revenue scenarios, risks and next steps

How we deliver

  1. Call and mutual NDA
  2. Desk research: TİTCK and SGK lists, Turkish medical literature, patient associations
  3. Structured interviews with independent neurologists, under written fair-market-value agreements
  4. Patient model with every assumption sourced
  5. Report and a one-hour presentation

Partnering

Partner selection

Find the right Turkish partner for your therapy, on terms you understand, through a structured and documented process.

Duration
6–10 weeks
Fee
Fixed, agreed in the proposal
Output
Shortlist, offer comparison and our recommendation
Discuss partner selection

You receive

  • A long list and a shortlist of qualified Turkish partners
  • A request for proposals sent on your behalf, under NDA
  • Side-by-side comparison of offers: commercial terms, regulatory capability, rare disease experience, compliance
  • Our recommendation and support up to a signed term sheet

Why us

  • We hold no product rights, so we have nothing to sell you
  • When we advise you, we take no fee from any partner on the same deal
  • We know which partners have launched which rare neurology therapies, and how

Foundation

Rare neurology intelligence for Türkiye

Behind every engagement is our own disease-by-disease map of Türkiye. Each layer feeds the assessments, partner searches and scouting briefs above.

Built only from public and aggregated sources. We hold no identifiable patient data.

Not sure which engagement fits?

Describe your situation and we will suggest where to start. Biotech companies usually start with an opportunity assessment; Turkish companies with a scouting brief.